Find My Journal

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

José Baselga, Ian Bradbury, Holger Eidtmann, Serena Di Cosimo, Evandro de Azambuja, Claudia Aura, Henry Gómez, Phuong Dinh, Karine Fauria, Veerle Van Dooren, Gursel Aktan, Aron Goldhirsch, Tsai-Wang Chang, Zsolt Horváth, M.A. Coccia-Portugal, Julien Dômont, Ling-Min Tseng, Georg Kunz, Joohyuk Sohn, Semiglazov Vf, Guillermo Lerzo, Markéta Palácová, Volodymyr Probachai, Lajos Pusztai, Michael Untch, Richard D. Gelber, Martine Piccart

The Lancet, 2012

Mass General Brigham, Massachusetts General Hospital, Harvard University, Queen's University Belfast, Frontier Agriculture (United Kingdom), Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Instituto Nacional de Enfermedades Neoplásicas, Breast International Group, GlaxoSmithKline (United States), European Institute of Oncology, National Cheng Kung University Hospital, National Institute of Oncology, Institut Gustave Roussy, National Yang Ming Chiao Tung University, Taipei Veterans General Hospital, St.-Johannes-Hospital Dortmund, Yonsei University, Institute of Oncology NN Petrov, Masaryk University, Regional Clinical Hospital named after II Mechnikov, The University of Texas MD Anderson Cancer Center, Charité - Universitätsmedizin Berlin, Dana-Farber Cancer Institute, Frontier Science & Technology Research Foundation, Institut Jules Bordet

View Free PDF Publisher Website

Abstract

An abstract is not available for this record. Please visit the publisher website for more details.

1305

Citations

View on Google Scholar